Is Gemtesa (vibegron) appropriate for treating bladder spasms in a quadriplegic patient with neurogenic bladder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Gemtesa for Bladder Spasms in Quadriplegic Patients

Gemtesa (vibegron) is an appropriate and guideline-supported option for treating bladder spasms in quadriplegic patients with neurogenic lower urinary tract dysfunction (NLUTD). The 2021 AUA/SUFU guidelines explicitly recommend beta-3 adrenergic receptor agonists like vibegron for improving bladder storage parameters in NLUTD patients 1.

Guideline Support

The most recent authoritative guidance comes from the 2021 AUA/SUFU NLUTD guidelines, which state that clinicians may recommend beta-3 adrenergic receptor agonists (like Gemtesa) to improve bladder storage parameters in NLUTD patients 1. This is a conditional recommendation with Grade C evidence, placing vibegron on equal footing with antimuscarinics for first-line pharmacotherapy.

Importantly, the guidelines note that antimuscarinics and beta-3 agonists can be used individually or in combination to optimize bladder storage 1. This flexibility is particularly relevant for quadriplegic patients who may have complex bladder dysfunction.

Clinical Evidence in Spinal Cord Injury

Recent research strongly supports vibegron's efficacy specifically in spinal cord injury populations:

  • A 2025 randomized crossover trial comparing vibegron to fesoterodine in spinal cord lesion patients found that vibegron significantly improved cystometric capacity and detrusor pressure, with 58% of patients preferring vibegron for continuation therapy due to better tolerability and fewer adverse events 2.

  • A 2022 retrospective study in acute SCI patients (within one year of injury) demonstrated that vibegron increased maximum cystometric capacity from 185 to 340 mL and improved bladder compliance from 8.3 to 20.0 mL/cmH₂O 3.

  • A 2025 systematic review concluded that beta-3 agonists represent a safe, effective, and well-tolerated first-line option in NLUTD management, with reassuring cardiovascular safety data and no cognitive adverse effects compared to antimuscarinics 4.

Practical Advantages for Quadriplegic Patients

Vibegron offers specific benefits over antimuscarinics that are particularly relevant for quadriplegic patients:

  • No anticholinergic side effects: Avoids dry mouth, constipation (already problematic in SCI), cognitive impairment, and blurred vision 2, 4
  • Once-daily dosing: 75 mg tablet taken with or without food 5
  • Can be crushed: Tablets may be crushed and mixed with applesauce if swallowing is difficult 5
  • No dose adjustment needed: Safe in renal impairment (eGFR ≥15 mL/min/1.73 m²) and mild-to-moderate hepatic impairment 5

Critical Safety Considerations

Monitor for urinary retention, especially if the patient is on concomitant antimuscarinics or has bladder outlet obstruction 5. The FDA label warns that vibegron may increase retention risk when combined with muscarinic antagonists.

Watch for angioedema: Though rare, this can be life-threatening and requires immediate discontinuation 5.

Ensure proper bladder management: Vibegron should be used alongside appropriate catheterization strategies. The guidelines strongly recommend clean intermittent catheterization (CIC) over indwelling catheters when feasible 1.

Treatment Algorithm

  1. Confirm neurogenic detrusor overactivity with urodynamic studies showing reduced bladder capacity (<200 mL), poor compliance (<20 mL/cmH₂O), or detrusor overactivity 3

  2. Initiate vibegron 75 mg once daily as first-line pharmacotherapy or add to existing antimuscarinic if inadequate response 1, 2

  3. Reassess at 4-12 weeks with urodynamic parameters and symptom assessment 2, 3

  4. If inadequate response, consider combination therapy with antimuscarinics or escalate to onabotulinumtoxin A injections 4, 6

  5. Monitor long-term for upper tract protection, UTI prevention, and quality of life 1

Common Pitfalls to Avoid

  • Don't assume all quadriplegics need the same approach: Bladder management depends on level of injury, hand function, and whether they can perform self-catheterization 1
  • Don't overlook autonomic dysreflexia risk: High-level SCI patients may experience this life-threatening complication from bladder distension 1
  • Don't use vibegron as monotherapy if retention is present: Ensure adequate bladder emptying strategy is in place first 5

The evidence strongly supports vibegron as an effective, well-tolerated option for managing bladder spasms in quadriplegic patients, with particular advantages in side effect profile compared to traditional antimuscarinics 2, 4, 6.

References

Related Questions

How should I manage nocturnal urge incontinence in a patient taking Gemtesa (vibegron)?
What is the recommended stepwise management for neurogenic bladder, including catheterization, anticholinergic or β3‑agonist therapy, and indications for botulinum toxin, sacral neuromodulation, or surgical reconstruction?
Can Complex Regional Pain Syndrome be diagnosed in a patient with an ankle injury three weeks after the trauma?
In a patient with chronic Lyme disease previously treated with doxycycline and amoxicillin who now has leg edema, purpuric purple skin lesions, and a skin biopsy showing superficial and deep perivascular and interstitial dermatitis with plasma cells and fibrosis suggestive of late-stage Lyme disease, what is the appropriate management?
What are the signs and symptoms of serotonin syndrome in a patient on aripiprazole and lithium who is initiating citalopram?
For Bell's palsy (idiopathic facial paralysis), should magnetic resonance imaging (MRI) be performed with gadolinium contrast or without?
Why is intravenous drug use a red flag in patients presenting with back pain?
In an adult with a hypomanic episode, which medication is most appropriate to provide both antimanic and hypnotic effects (e.g., olanzapine)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.